These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18260953)

  • 1. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 3. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 4. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of cardiovascular disease in type 2 diabetic patients].
    Yokota C
    Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.
    Holman RR
    Nat Rev Endocrinol; 2018 Feb; 14(2):67-68. PubMed ID: 29302077
    [No Abstract]   [Full Text] [Related]  

  • 7. Legacy effect in medicine-the expanding horizon!
    Wander GS; Bansal M
    Indian Heart J; 2018; 70(6):769-771. PubMed ID: 30580842
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome results renew debate about diabetes drug development.
    Mullard A
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):179-80. PubMed ID: 24622363
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality of healthcare in type 2 diabetes mellitus in Spain].
    Soriguer F; Ruiz de Adana MS
    Med Clin (Barc); 2012 May; 138(12):522-4. PubMed ID: 22118976
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.
    Saxon DR; Rasouli N; Eckel RH
    Drugs; 2018 Feb; 78(2):203-214. PubMed ID: 29305768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 15. ADVANCE trial of great importance in preventing cardiovascular deaths in type 2 diabetes.
    Cardiovasc J Afr; 2007; 18(5):343-4. PubMed ID: 17985038
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.
    Chilton RJ; Dungan KM; Shubrook JH; Umpierrez GE
    Prim Care Diabetes; 2020 Jun; 14(3):193-212. PubMed ID: 31704161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
    Górriz JL; Cos Claramunt FX; Duque N; Matali A
    Prim Care Diabetes; 2019 Dec; 13(6):485-494. PubMed ID: 31400992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Revised blood pressure goals and no elevated glucose readings in between].
    MMW Fortschr Med; 2005 Dec; 147(51-52):72. PubMed ID: 16402718
    [No Abstract]   [Full Text] [Related]  

  • 19. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

  • 20. A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety.
    Fitchett D; Cheng A; Connelly K; Goldenberg R; Goodman SG; Leiter LA; Lonn E; Paty B; Poirier P; Stone J; Thompson D; Yale JF; Mancini GBJ
    Can J Cardiol; 2017 Jul; 33(7):940-942. PubMed ID: 28668144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.